Prior Evidence of Putative NovelRhinovirusSpecies, Australia
Year: 2008
Type: letter
Abstract: plant, and pulmonary infection with M. kansasii developed in 2 recipients of lung transplants (5).There is also a case report of systemic M. bovis infection developing in a patient with relapsing B chronic lymphocytic leukemia after administration of alemtuzumab (10).Although we believe that alemtuzumab is responsible for the severe immunosuppression that predisposed these patients to M. haemophilum infection, other explanations are plausible.For example, patient 1 had received rituximab and cyclophosamide for 6 months.These drugs, in addition to his underlying disease of chromic lymphocytic leukemia, may have predisposed him to M. haemophilum infection.However, his lesions did not appear until he received alemtuzumab.In patient 2, the immunosuppression associated with his transplant may have predisposed the patient to M. haemophilum infection.This report identifi es M. haemophilum as an opportunistic pathogen in patients who have received alemtuzumab.We recommend that all patients who have received at least 1 dose of alemtuzumab, and who have undiagnosed tender skin lesions located over the extremities, be evaluated by using appropriate techniques to isolate M. haemophilum.
Source: Emerging infectious diseases
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W1983213946